Immunocore to present at upcoming investor conferences
April 04, 2024 16:00 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore”...
Immunocore to present at upcoming investor conferences
September 11, 2023 17:00 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
April 18, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated...
Immunocore to present four posters at AACR Annual Meeting 2023
March 14, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing...
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
February 23, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 February, 2023) Immunocore...
Immunocore to present at upcoming investor conferences
February 01, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
January 09, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024 KIMMTRAK (tebentafusp-tebn) approved in over 30 countries with continued global expansion in 2023-2024;...
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
December 08, 2022 06:30 ET
|
Immunocore Holdings Limited
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4...
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
August 03, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc...
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
June 25, 2022 04:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...